ArticleBMC gastroenterology2026
The impact of metabolic dysfunction-associated steatotic liver disease on non-invasive fibrosis scores in patients with chronic hepatitis B: a multicenter retrospective study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe coexistence of metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic hepatitis B (CHB) may influence liver fibrosis, but the relationship between these conditions remains unclear. MASLD may also affect the performance of non-invasive tests (NITs) in CHB. Recently developed NITs, such as FIB-8 and FIB-9, were designed for MASLD patients but have not been assessed in those with both CHB and MASLD. This study aimed to comparatively assess the diagnostic performance of various NITs for predicting significant fibrosis in CHB patients stratified by MASLD status.
methodsIn this multicenter retrospective study, CHB patients who underwent liver biopsy were analyzed. Significant fibrosis was defined as ISHAK stage ≥ 3, and hepatic steatosis as ≥ 5% fat accumulation on biopsy. The performance of 20 NITs in predicting significant fibrosis was assessed in the overall cohort and in MASLD-positive and MASLD negative groups.
resultsA total of 1545 patients were included, of whom 328 (21.2%) were MASLD-positive. More than half of the MASLD-positive patients had a single cardiometabolic risk factor. In the MASLD-negative group, FIB-4 showed the highest area under the receiver operating characteristic curve (AUROC) value (0.660), whereas in the MASLD-positive group, the highest AUROC was observed for FIB-8 (0.728). Furthermore, the FIB-8, Lok, and ATA scores demonstrated significantly higher AUROC values in the MASLD-positive group than in the MASLD-negative group (0.728, 0.726, and 0.716 vs. 0.535, 0.590, and 0.600, respectively; p = 0.008, 0.002, and 0.008). No significant differences were observed in the performance of the remaining NITs according to MASLD status.
conclusionsThe diagnostic performance of NITs for predicting significant fibrosis in CHB patients varies according to MASLD status. FIB-8, Lok, and ATA scores demonstrated significantly higher diagnostic accuracy in MASLD-positive patients, suggesting that metabolic factors may influence the discriminative capacity of fibrosis markers. Nevertheless, all evaluated NITs demonstrated low-to-moderate diagnostic performance across all groups, limiting their standalone clinical utility and highlighting the need for more accurate non-invasive fibrosis models in this population.
trial registrationNot applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.